CN101167714A - Medicine for treating male erectile dysfunction - Google Patents
Medicine for treating male erectile dysfunction Download PDFInfo
- Publication number
- CN101167714A CN101167714A CNA2007100535904A CN200710053590A CN101167714A CN 101167714 A CN101167714 A CN 101167714A CN A2007100535904 A CNA2007100535904 A CN A2007100535904A CN 200710053590 A CN200710053590 A CN 200710053590A CN 101167714 A CN101167714 A CN 101167714A
- Authority
- CN
- China
- Prior art keywords
- medicine
- medicament
- erectile dysfunction
- male erectile
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicament for the treatment of functional disturbance of men's erection, which is made up of L-arginine with the mass ratio of 30-95% and a solid agent or a liquid agent with the mass ratio of 5-70%. The medicament can be made into capsules, drinkable solution, pills, and tablets, dripping or spraying agent, suppository or patches. The medicament can be take by oral administration, or administered through tongue, nasal cavity, rectal intestine, or skin, and the medicament which contains L-arginine of 1-2.7 g, 2.9-4.9 g, or 5.1-10.0 g is taken everyday for 2- 8 weeks or more constantly or discontinuously. The medicament has the advantages of low price, good erecting effect, high safety, few side effects, and many aggregate effects, and the medicament also can improve the heart functions of patients who suffer form congestive heart failures, enhance immunologic function, and prevent oxidation, age and arteriosclerosis. The invention is safer than Viagra for patients who suffer ED and especially the patients who have had heart disease.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of male erectile dysfunction, belong to medicine field
Background technology
Male erectile dysfunction is a global medical problem, shows according to domestic and international relevant statistics: the whole world has and surpasses 100,000,000 male and suffer from various degree ED.Find that moderate to the prevalence of complete ED reaches 40% in the male's investigation in 40～70 years old of Great Britain and France two countries.Domesticly Beijing, Chongqing, Guangzhou 2226 routine adult males are carried out survey result show: the total prevalence rate of ED is 26.1%, and 40 years old and above crowd's prevalence is 40.2%.The patient often agonizes because can't carry out normal sexual life, and mental pressure and social pressure are big especially, have a strong impact on patients ' life quality.
At present existing oral drug therapy male erectile dysfunction is as α receptor antagonist (phentolamine, Yohimbine), phosphodiesterase inhibitor (sldenafil), central nervous system's agonist (apomorphine), 5 one seretonine receptor 5 antagonisies (trazodone) etc.Wherein ideal with the curative effect of sldenafil, total effective rate is 70%, but side effect such as this medicine can produce the dimness of vision, headache, blushes, blood pressure drops, and cost an arm and a leg, limited its extensive use.Therefore studying and produce a kind of safe, effective, inexpensive, medicine that be easy to use, have no side effect is patient's serious hope, has far-reaching social meaning.
Summary of the invention
Purpose of the present invention just provides a kind of medicine for the treatment of male erectile dysfunction, its effective ingredient is the L-arginine, improve patient's sexual function situation by long-term prescription, reach the effect of treatment male erectile dysfunction, and do not have other side effect, strengthen patient's immunocompetence simultaneously and improve defying age, antioxidative ability.
Realize that the technical scheme that the object of the invention adopts is: a kind of medicine for the treatment of male erectile dysfunction, formulated by following mass ratio: L-arginine 30～95%, solid agent or liquid shape agent 5～70%.
This medicine can be made into capsule, drinkable solution, pill, tablet, dropping or spray, suppository or paster.Can take every day and contain 1～2.7g, 2.9～4.9g or arginic this medicine of 5.1～10.0g L-by oral, Sublingual, nasal cavity, rectum or percutaneous drug delivery, lasting or interruption is taken 2～8 weeks or longer time.
The L-arginine that is absorbed into blood is transported through the cell membrane transporter body and is stored in the cell in the born of the same parents in the pond, under nitricoxide synthase and coenzyme effect, catalysis L-arginine changes nitric oxide and L-citrulline, also can strengthen the activity of nitricoxide synthase simultaneously, nitric oxide produces the back because it has lipotropy, but permeate through cell membranes also is diffused in the contiguous smooth muscle cell, and act on water solublity guanylate cyclase (sGC) in the smooth muscle cell, activate this enzyme, cyclic adenosine monophosphate (cGMP) is produced increase.And cGMP is one of second message,second messenger important in the body, and it can produce a series of physiological reactions, as diastole diastole spongy body smooth muscle, blood vessel dilating, nerve information transmission and to the adjusting of hypothalamus-hypophysis-target gland axle etc., brings out the erection of penis.
Nitric oxide in the erection process-cyclic guanosine monophosphate path plays an important role in erection, the L-arginine is as the main donor of human body endogenous nitric oxide, in vivo can be by improving content of nitric oxide and nitric oxide synthase activity thereof in the penile tissue, increase blood oxygen pressure in the penile tissue, regulate the effect that hypothalamus-hypophysis-target gland axle is brought into play the treatment male erectile dysfunction.
The present invention has following advantage: the medicine ratio of the present invention and other treatment treatment male erectile dysfunction, have cheap, erections is effective, degree of safety is high, have no side effect, advantage such as more than the comprehensive effect.L-arginine among the present invention has good effect to improving cardiovascular elasticity in addition, and it can also improve cardiac function, raise immunity, defying age, antioxidation, the arteriosclerosis of congested heart failure patient.Therefore, for suffering from ED, especially for the patient that HDH is arranged, it is more safer than viagra.
The specific embodiment
Embodiment 1
By long-term oral sildenafil citrate (viagra) and medicine provided by the invention to strengthening the contrast of penile erectile function curative effect.
Feed male SD rat and contain 2.25g/kgd, the arginic medicine of 4.5g/kgd L-and 45mg/kgd group sildenafil citrate after eight weeks, the result shows, above-mentioned each group all can improve the erection function of rat, the inductive rat intracavernous pressure of electricity irritation is not taken medicine to organize and is significantly improved, content of nitric oxide and nitric oxide synthase activity thereof all obviously improve in serum and the penile tissue, and GSH content and SOD activity also strengthen in the serum; Take L-arginine small dose group (2.25g/kgd) action effect and be better than heavy dose of group (4.5g/kgd), and the action effect of taking L-arginine small dose group is with to take 45mg/kgd group sildenafil citrate group action effect suitable, even slightly is better than 45mg/kgd sildenafil citrate group.
Take the erection function that medicine provided by the invention can improve rat equally for a long time, have the curative effect identical with sildenafil citrate, and do not produce the dimness of vision, headache, blush, side effect such as blood pressure drops.
Claims (4)
1. a medicine for the treatment of male erectile dysfunction is characterized in that it is formulated by following mass ratio: L-arginine 30～95%, solid agent or liquid shape agent 5～70%.
2. a kind of medicine for the treatment of male erectile dysfunction according to claim 1 is characterized in that: this medicine can be made into capsule, drinkable solution, pill, tablet, dropping or spray, suppository or paster.
3. a kind of medicine for the treatment of male erectile dysfunction according to claim 1 is characterized in that: this medicine can be by oral, Sublingual, nasal cavity, rectum or percutaneous drug delivery.
4. a kind of medicine for the treatment of male erectile dysfunction according to claim 1 is characterized in that: take every day and contain 1～2.7g, 2.9～4.9g or arginic this medicine of 5.1～10.0g L-, lasting or interruption is taken 2～8 weeks or longer time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100535904A CN101167714A (en) | 2007-10-19 | 2007-10-19 | Medicine for treating male erectile dysfunction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100535904A CN101167714A (en) | 2007-10-19 | 2007-10-19 | Medicine for treating male erectile dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101167714A true CN101167714A (en) | 2008-04-30 |
Family
ID=39388564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100535904A Pending CN101167714A (en) | 2007-10-19 | 2007-10-19 | Medicine for treating male erectile dysfunction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101167714A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103402530A (en) * | 2010-10-19 | 2013-11-20 | K.L.R.M.公司 | Compositions and methods for treating erectile dysfunction |
| CN104736150A (en) * | 2012-08-20 | 2015-06-24 | "Parafarm"有限责任公司 | Method for restoring male sex drive (libido) using a food supplement for restoring male sex drive (libido) |
| CN105935444A (en) * | 2016-05-27 | 2016-09-14 | 中山大学 | Application of anti-PEDF monoclonal antibody in erectile dysfunction disease of male diabetic patients |
| CN107847476A (en) * | 2015-07-13 | 2018-03-27 | 协和发酵生化株式会社 | Containing the arginic tablet of high concentration |
-
2007
- 2007-10-19 CN CNA2007100535904A patent/CN101167714A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103402530A (en) * | 2010-10-19 | 2013-11-20 | K.L.R.M.公司 | Compositions and methods for treating erectile dysfunction |
| CN103402530B (en) * | 2010-10-19 | 2017-07-28 | K.L.R.M.公司 | Constituent and method for treating erectile dysfunction |
| CN104736150A (en) * | 2012-08-20 | 2015-06-24 | "Parafarm"有限责任公司 | Method for restoring male sex drive (libido) using a food supplement for restoring male sex drive (libido) |
| CN104736150B (en) * | 2012-08-20 | 2017-09-08 | "Parafarm"有限责任公司 | The method that man's sexual desire (Libido) is restored is realized using the dietary supplements of man's sexual desire (Libido) recovery effect |
| CN107847476A (en) * | 2015-07-13 | 2018-03-27 | 协和发酵生化株式会社 | Containing the arginic tablet of high concentration |
| CN105935444A (en) * | 2016-05-27 | 2016-09-14 | 中山大学 | Application of anti-PEDF monoclonal antibody in erectile dysfunction disease of male diabetic patients |
| CN105935444B (en) * | 2016-05-27 | 2019-11-12 | 中山大学 | Application of the anti-PEDF monoclonal antibody in diabetic men erectile dysfunction disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104662007B (en) | Cystathionine gamma lyase (CSE) inhibitor | |
| US20060188575A1 (en) | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | |
| CN103167877A (en) | Compositions comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof | |
| Nierenberg et al. | Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome | |
| MXPA04012070A (en) | Therapeutic agent for overactive bladder. | |
| CN101167714A (en) | Medicine for treating male erectile dysfunction | |
| CN103269699A (en) | Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin | |
| JP2021113239A (en) | Composition for improvement or prevention of symptoms of parkinson's disease | |
| CN101237862B (en) | Compositions comprising an no donor and a dithiolane and their use for improvement of sexual function | |
| CN101953825A (en) | Anti-alcohol composition and application thereof in preparation of health-care products | |
| King et al. | Effect of intravenous injection of marihuana | |
| Swartz et al. | Hyperlithemia correction and persistent delirium | |
| Moore et al. | Nonsteroidal Anti-inflammatory Intolerance: An Anaphylactic Reaction to Tolmetin | |
| CN107115332A (en) | It is a kind of to be used to treat composition of motor neuron disease and application thereof | |
| TWI670059B (en) | Uses of gallocatechin | |
| RU2165759C1 (en) | Method for treating alcohol intoxication | |
| CN102266342B (en) | Application of riboflavin tetrabutyrate to preparation of anxiolytic medicament | |
| CN118976093A (en) | Use of gamma-glutamylcysteine for preventing peripheral nerve cell injury caused by chemotherapeutic drugs | |
| Fyfe et al. | Myopathy and hypokalaemia in carbenoxolone therapy. | |
| CN101444507A (en) | Pharmaceutical composition for treating type 2 diabetes | |
| CN104337702A (en) | Mouth caring article suitable for patient with diabetes | |
| EP1621193A2 (en) | Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators | |
| Whitlock | Swedish social mores | |
| Spencer | Recognition of Voluntary Work in Hospitals | |
| Williams | Towel Clip Trauma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080430 |